Can a new tracer light up cancer growth?
NCT ID NCT00935090
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and diagnose cancer, and possibly predict how well a patient might respond to treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- A radioactive tracer called FLT, injected into the vein, used with a PET scan to measure tumor growth.
- What this could lead to
- If successful, this imaging method could help doctors detect cancer more accurately and plan better treatments.
- What could go wrong
- This is an early-phase trial, so the tracer may not work as hoped or may not be widely available. There are also risks from radiation exposure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Started
-
Sep 2009
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 120 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
DISEASE CHARACTERISTICS: * Meets one of the following criteria: * Histologically confirmed solid tumor or hematologic malignancy * Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging PATIENT CHARACTERISTICS: * Able to lie still in the PET scanner * Girth and weight must be suitable to enter the gantry * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: * Not specified
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Brain and central nervous system tumors are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
- Can regional data improve bone marrow transplant results for blood cancers?
- Could a frailty score predict which older cancer patients survive intensive care?
- Can a new drug shield kidneys from chemotherapy damage?
- Can adding venetoclax make donor stem cell transplants safer for High-Risk blood cancers?
- Double-Drug attack on Hard-to-Treat lymphomas